1. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer;Baselga;J Clin Oncol,1996
2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol,1998
3. U.S. Food & Drug Administration. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products 2021. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products (accessed September 10, 2021).
4. U.S. Food & Drug Administration. FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia 2018. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-relapsed-or-refractory-acute-myeloid-leukemia (accessed August 15, 2021).
5. U.S. Food & Drug Administration. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma (accessed August 26, 2021).